PRESS RELEASE

Groningen, The Netherlands, 31 may 2010

Mucosis receives financial support from the dutch government for its FluGEM program

--> Download the pdf

Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM™ clinical development program is concluded successfully.

“We are really pleased with the government’s financial support. This non-dilutive funding underlines the progress we have made so far and, even more importantly, strengthens our financial capabilities going forward. It will enable us to generate proof of efficacy with FluGEM® in man” said Govert Schouten, CEO of Mucosis.

Mucosis develops novel vaccines on the basis of its unique Mimopath® technology. This invention is key to the growth strategy for the coming years.

For further information please contact:

Govert Schouten
CEO Mucosis
+31 (6) 55320948
govert.schouten@mucosis.com
www.mucosis.com
 

About Mucosis
Mucosis B.V. is a Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidates are FluGEM®, an intranasal vaccine to prevent influenza, and PneuGEM®, a vaccine preventing diseases caused by pneumococcal bacteria. Mucosis’s vaccines are based on the patented Mimopath® technology. This technology enables a more natural immune response as well as a broad base of protection.

About Mimopathv technology
Mimopath® technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed an easy technique to formulate the L. lactis bacteria into non-living particles that can be loaded with antigens from viral, bacterial, or parasitic origin. The antigen-covered particles form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >